With reference to letter dated 31 July 2023 intimating the date of the Board Meeting for consideration of the unaudited standalone and consolidated financial results for the quarter ended 30 June 2023 and pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that Board of Directors, in its Meeting held today, have approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2023, as recommended by Audit Committee. It attached approved unaudited standalone and consolidated financial results and limited review reports. A Press Release issued in this regard will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 11:03 am (IST) and concluded at 12:01 pm (IST).
The above information is a part of company’s filings submitted to BSE.